Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to determine apoptotic signaling pathways such as Survivin, Bcl-2, Bax, c-Myc and caspase-9 expression levels in rats model with iatrogenic endometrial hyperplasia after metformin and medroxyprogesterone acetate administration.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group | Active Comparator | Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia |
|
| Metformin group | Active Comparator | Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days |
|
| Medroxyprogesterone acetate group | Active Comparator | Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 17β estradiol hemihydrate | Drug | 4mg/kg/day for 20 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Survivin Gene Expression Levels in Rat Uterine Tissue | 4 months | |
| Bcl-2 Gene Expression Levels in Rat Uterine Tissue | 4 months | |
| Bax Gene Expression Levels in Rat Uterine Tissue | 4 months | |
| c-Myc Gene Expression Levels in Rat Uterine Tissue | 4 months | |
| Caspase-9 Expression Levels in Rat Uterine Tissue | 4 months |
Not provided
Not provided
Inclusion criteria:
Forty-eight weeks old female Wistar-Albino rats, weighting between 180 and 260 g
Exclusion criteria.
We have no exclusion criteria because we examine drugs effects in the experimental rats
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Erdem SAHÄ°N | Kayseri Training and Research Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kayseri Training and Research Hospital | Kayseri | 38000 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D004714 | Endometrial Hyperplasia |
| D016889 | Endometrial Neoplasms |
| ID | Term |
|---|---|
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| D017258 | Medroxyprogesterone Acetate |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D008525 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Metformin | Drug | 50 mg/kg/day last 10 days |
|
| medroxyprogesterone acetate | Drug | 1mg/kg/day last 10 days |
|
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D014594 | Uterine Neoplasms |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| Medroxyprogesterone |
| D006908 | Hydroxyprogesterones |
| D011374 | Progesterone |
| D011282 | Pregnenediones |
| D011283 | Pregnenes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |